{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:05:07Z","timestamp":1793783107268,"version":"4.6.1"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1038\/s41569-023-00901-2","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T18:11:51Z","timestamp":1689876711000},"page":"830-844","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9286-1451","authenticated-orcid":false,"given":"Diana A.","family":"Gorog","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1202-9575","authenticated-orcid":false,"given":"Jose Luis","family":"Ferreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Ahrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6645-6404","authenticated-orcid":false,"given":"Junya","family":"Ako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun","family":"Halvorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7934-5524","authenticated-orcid":false,"given":"Kurt","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0403-3726","authenticated-orcid":false,"given":"Young-Hoon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliano P.","family":"Navarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rubboli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Sibbing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta M.","family":"Siller-Matula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6677-6229","authenticated-orcid":false,"given":"Robert F.","family":"Storey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack W. C.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurrien M.","family":"ten Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Vandenbriele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"key":"901_CR1","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"JP Collet","year":"2021","unstructured":"Collet, J. P. et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 42, 1289\u20131367 (2021).","journal-title":"Eur. Heart J."},{"key":"901_CR2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez, B. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 39, 119\u2013177 (2018).","journal-title":"Eur. Heart J."},{"key":"901_CR3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","volume":"40","author":"FJ Neumann","year":"2019","unstructured":"Neumann, F. J. et al. 2018 ESC\/EACTS guidelines on myocardial revascularization. Eur. Heart J. 40, 87\u2013165 (2019).","journal-title":"Eur. Heart J."},{"key":"901_CR4","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742c84","volume":"127","author":"PT O\u2019Gara","year":"2013","unstructured":"O\u2019Gara, P. T. et al. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation 127, e362\u2013e425 (2013).","journal-title":"Circulation"},{"key":"901_CR5","first-page":"e344","volume":"130","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam, E. A. et al. 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation 130, e344\u2013e426 (2014).","journal-title":"Circulation"},{"key":"901_CR6","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1161\/CIRCULATIONAHA.121.058519","volume":"145","author":"JS Lawton","year":"2022","unstructured":"Lawton, J. S. et al. 2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation 145, e4\u2013e17 (2022).","journal-title":"Circulation"},{"key":"901_CR7","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","volume":"389","author":"F Costa","year":"2017","unstructured":"Costa, F. et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 389, 1025\u20131034 (2017).","journal-title":"Lancet"},{"key":"901_CR8","doi-asserted-by":"crossref","first-page":"h1618","DOI":"10.1136\/bmj.h1618","volume":"350","author":"EP Navarese","year":"2015","unstructured":"Navarese, E. P. et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ 350, h1618 (2015).","journal-title":"BMJ"},{"key":"901_CR9","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin, L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045\u20131057 (2009).","journal-title":"N. Engl. J. Med."},{"key":"901_CR10","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott, S. D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001\u20132015 (2007).","journal-title":"N. Engl. J. Med."},{"key":"901_CR11","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2022-001999","volume":"9","author":"M Pufulete","year":"2022","unstructured":"Pufulete, M. et al. Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a \u2018target trial\u2019.Open Heart 9, e001999 (2022).","journal-title":"Open Heart"},{"key":"901_CR12","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","volume":"385","author":"M Valgimigli","year":"2021","unstructured":"Valgimigli, M. et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N. Engl. J. Med. 385, 1643\u20131655 (2021).","journal-title":"N. Engl. J. Med."},{"key":"901_CR13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1055\/s-0038-1676545","volume":"119","author":"J Kang","year":"2019","unstructured":"Kang, J. et al. Racial differences in ischaemia\/bleeding risk trade-off during anti-platelet therapy: individual patient level landmark meta-analysis from seven RCTs. Thromb. Haemost. 119, 149\u2013162 (2019).","journal-title":"Thromb. Haemost."},{"key":"901_CR14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023337","volume":"9","author":"N Ismail","year":"2019","unstructured":"Ismail, N. et al. Incidence and prognostic impact of post discharge bleeding post acute coronary syndrome within an outpatient setting: a systematic review. BMJ Open. 9, e023337 (2019).","journal-title":"BMJ Open."},{"key":"901_CR15","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","volume":"114","author":"JW Eikelboom","year":"2006","unstructured":"Eikelboom, J. W. et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114, 774\u2013782 (2006).","journal-title":"Circulation"},{"key":"901_CR16","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013679","volume":"8","author":"N Ismail","year":"2019","unstructured":"Ismail, N. et al. Bleeding after hospital discharge following acute coronary syndrome: incidence, types, timing, and predictors. J. Am. Heart Assoc. 8, e013679 (2019).","journal-title":"J. Am. Heart Assoc."},{"key":"901_CR17","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010956","volume":"8","author":"G Crimi","year":"2019","unstructured":"Crimi, G. et al. Time course of ischemic and bleeding burden in elderly patients with acute coronary syndromes randomized to low-dose prasugrel or clopidogrel. J. Am. Heart Assoc. 8, e010956 (2019).","journal-title":"J. Am. Heart Assoc."},{"key":"901_CR18","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.jacc.2013.02.044","volume":"61","author":"AP Amin","year":"2013","unstructured":"Amin, A. P. et al. Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status. J. Am. Coll. Cardiol. 61, 2130\u20132138 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"901_CR19","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1055\/a-1346-3300","volume":"121","author":"YH Jeong","year":"2021","unstructured":"Jeong, Y. H. et al. Pharmacodynamic profile and prevalence of bleeding episode in East Asian patients with acute coronary syndromes treated with prasugrel standard-dose versus de-escalation strategy: a randomized A-MATCH trial. Thromb. Haemost. 121, 1376\u20131386 (2021).","journal-title":"Thromb. Haemost."},{"key":"901_CR20","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1093\/eurheartj\/ehz202","volume":"40","author":"D Aradi","year":"2019","unstructured":"Aradi, D. et al. Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial. Eur. Heart J. 40, 1942\u20131951 (2019).","journal-title":"Eur. Heart J."},{"key":"901_CR21","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jacc.2016.02.064","volume":"67","author":"U Baber","year":"2016","unstructured":"Baber, U. et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS. J. Am. Coll. Cardiol. 67, 2224\u20132234 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"901_CR22","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","volume":"315","author":"RW Yeh","year":"2016","unstructured":"Yeh, R. W. et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 315, 1735\u20131749 (2016).","journal-title":"JAMA"},{"key":"901_CR23","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","volume":"40","author":"P Urban","year":"2019","unstructured":"Urban, P. et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur. Heart J. 40, 2632\u20132653 (2019).","journal-title":"Eur. Heart J."},{"key":"901_CR24","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1253\/circj.CJ-19-1109","volume":"84","author":"M Nakamura","year":"2020","unstructured":"Nakamura, M. et al. JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease. Circ. J. 84, 831\u2013865 (2020).","journal-title":"Circ. J."},{"key":"901_CR25","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","volume":"116","author":"SD Wiviott","year":"2007","unstructured":"Wiviott, S. D. et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116, 2923\u20132932 (2007).","journal-title":"Circulation"},{"key":"901_CR26","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jacc.2010.03.100","volume":"56","author":"RF Storey","year":"2010","unstructured":"Storey, R. F. et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J. Am. Coll. Cardiol. 56, 1456\u20131462 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"901_CR27","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1161\/CIRCULATIONAHA.118.034790","volume":"138","author":"RC Orme","year":"2018","unstructured":"Orme, R. C. et al. Study of two dose regimens of ticagrelor compared with clopidogrel in patients undergoing percutaneous coronary intervention for stable coronary artery disease. Circulation 138, 1290\u20131300 (2018).","journal-title":"Circulation"},{"key":"901_CR28","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"S Yusuf","year":"2001","unstructured":"Yusuf, S. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345, 494\u2013502 (2001).","journal-title":"N. Engl. J. Med."},{"key":"901_CR29","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","volume":"381","author":"S Schupke","year":"2019","unstructured":"Schupke, S. et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N. Engl. J. Med. 381, 1524\u20131534 (2019).","journal-title":"N. Engl. J. Med."},{"key":"901_CR30","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","volume":"381","author":"R Mehran","year":"2019","unstructured":"Mehran, R. et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N. Engl. J. Med. 381, 2032\u20132042 (2019).","journal-title":"N. Engl. J. Med."},{"key":"901_CR31","doi-asserted-by":"crossref","first-page":"1053867","DOI":"10.3389\/fcvm.2022.1053867","volume":"9","author":"MG Kang","year":"2022","unstructured":"Kang, M. G. et al. Prevalence of adverse events during ticagrelor versus clopidogrel treatment and its association with premature discontinuation of dual antiplatelet therapy in East Asian patients with acute coronary syndrome. Front. Cardiovasc. Med. 9, 1053867 (2022).","journal-title":"Front. Cardiovasc. Med."},{"key":"901_CR32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jacc.2010.03.048","volume":"56","author":"D Sibbing","year":"2010","unstructured":"Sibbing, D., Steinhubl, S. R., Schulz, S., Schomig, A. & Kastrati, A. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J. Am. Coll. Cardiol. 56, 317\u2013318 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"901_CR33","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1093\/eurheartj\/ehu158","volume":"35","author":"M Sousa-Uva","year":"2014","unstructured":"Sousa-Uva, M. et al. Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. Eur. Heart J. 35, 1510\u20131514 (2014).","journal-title":"Eur. Heart J."},{"key":"901_CR34","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2102137","volume":"384","author":"WS Jones","year":"2021","unstructured":"Jones, W. S. et al. Comparative effectiveness of aspirin dosing in cardiovascular disease. N. Engl. J. Med. 384, 1981\u20131990 (2021).","journal-title":"N. Engl. J. Med."},{"key":"901_CR35","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","volume":"363","author":"CURRENT-OASIS 7 Investigators","year":"2010","unstructured":"CURRENT-OASIS 7 Investigators et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N. Engl. J. Med. 363, 930\u2013942 (2010).","journal-title":"N. Engl. J. Med."},{"key":"901_CR36","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","volume":"33","author":"L Friberg","year":"2012","unstructured":"Friberg, L., Rosenqvist, M. & Lip, G. Y. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur. Heart J. 33, 1500\u20131510 (2012).","journal-title":"Eur. Heart J."},{"key":"901_CR37","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1055\/s-0042-1750385","volume":"122","author":"DA Gorog","year":"2022","unstructured":"Gorog, D. A. et al. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and Asia-Pacific expert consensus paper. Thromb. Haemost. 122, 1625\u20131652 (2022).","journal-title":"Thromb. Haemost."},{"key":"901_CR38","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0040-1718729","volume":"121","author":"HK Kim","year":"2021","unstructured":"Kim, H. K. et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb. Haemost. 121, 422\u2013432 (2021).","journal-title":"Thromb. Haemost."},{"key":"901_CR39","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/clc.22583","volume":"39","author":"J Abtan","year":"2016","unstructured":"Abtan, J. et al. Residual ischemic risk and its determinants in patients with previous myocardial infarction and without prior stroke or TIA: insights from the REACH registry. Clin. Cardiol. 39, 670\u2013677 (2016).","journal-title":"Clin. Cardiol."},{"key":"901_CR40","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.acvd.2009.12.003","volume":"103","author":"M Lafitte","year":"2010","unstructured":"Lafitte, M. et al. After acute coronary syndrome, diabetic patients with peripheral vascular disease remain at high risk of cardiovascular events despite secondary prevention measures. Arch. Cardiovasc. Dis. 103, 97\u2013105 (2010).","journal-title":"Arch. Cardiovasc. Dis."},{"key":"901_CR41","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/2048872618761621","volume":"7","author":"S Leonardi","year":"2018","unstructured":"Leonardi, S. et al. Optimised care of elderly patients with acute coronary syndrome. Eur. Heart J. Acute Cardiovasc. Care 7, 287\u2013295 (2018).","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"901_CR42","doi-asserted-by":"crossref","first-page":"975969","DOI":"10.3389\/fcvm.2022.975969","volume":"9","author":"M Galli","year":"2022","unstructured":"Galli, M. & Angiolillo, D. J. De-escalation of antiplatelet therapy in acute coronary syndromes: why, how and when. Front. Cardiovasc. Med. 9, 975969 (2022).","journal-title":"Front. Cardiovasc. Med."},{"key":"901_CR43","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.jacc.2016.07.760","volume":"68","author":"G Giustino","year":"2016","unstructured":"Giustino, G. et al. Efficacy and safety of dual antiplatelet therapy after complex PCI. J. Am. Coll. Cardiol. 68, 1851\u20131864 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"901_CR44","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ijcard.2012.01.080","volume":"167","author":"F D\u2019Ascenzo","year":"2013","unstructured":"D\u2019Ascenzo, F. et al. Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int. J. Cardiol. 167, 575\u2013584 (2013).","journal-title":"Int. J. Cardiol."},{"key":"901_CR45","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/09537104.2017.1280601","volume":"28","author":"R Gosling","year":"2017","unstructured":"Gosling, R. et al. Comparison of P2Y(12) inhibitors for mortality and stent thrombosis in patients with acute coronary syndromes: single center study of 10 793 consecutive \u2018real-world\u2019 patients. Platelets 28, 767\u2013773 (2017).","journal-title":"Platelets"},{"key":"901_CR46","first-page":"1034","volume":"38","author":"T Palmerini","year":"2017","unstructured":"Palmerini, T. et al. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur. Heart J. 38, 1034\u20131043 (2017).","journal-title":"Eur. Heart J."},{"key":"901_CR47","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1161\/CIRCULATIONAHA.106.180944","volume":"115","author":"CL Grines","year":"2007","unstructured":"Grines, C. L. et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 115, 813\u2013818 (2007).","journal-title":"Circulation"},{"key":"901_CR48","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1001\/jama.293.17.2126","volume":"293","author":"I Iakovou","year":"2005","unstructured":"Iakovou, I. et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293, 2126\u20132130 (2005).","journal-title":"JAMA"},{"key":"901_CR49","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1161\/CIRCULATIONAHA.106.618066","volume":"113","author":"JA Spertus","year":"2006","unstructured":"Spertus, J. A. et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113, 2803\u20132809 (2006).","journal-title":"Circulation"},{"key":"901_CR50","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/joic.12413","volume":"30","author":"B Zwart","year":"2017","unstructured":"Zwart, B., Godschalk, T. C., Kelder, J. C. & Ten Berg, J. M. High risk of stent thrombosis in the first 6 months after coronary stenting: do not discontinue clopidogrel early after ACS. J. Interv. Cardiol. 30, 421\u2013426 (2017).","journal-title":"J. Interv. Cardiol."},{"key":"901_CR51","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.amjcard.2018.11.051","volume":"123","author":"M Schoos","year":"2019","unstructured":"Schoos, M. et al. Patterns and impact of dual antiplatelet cessation on cardiovascular risk after percutaneous coronary intervention in patients with acute coronary syndromes. Am. J. Cardiol. 123, 709\u2013716 (2019).","journal-title":"Am. J. Cardiol."},{"key":"901_CR52","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","volume":"65","author":"G Giustino","year":"2015","unstructured":"Giustino, G. et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol. 65, 1298\u20131310 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"901_CR53","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1055\/s-0040-1712449","volume":"120","author":"H Kawashima","year":"2020","unstructured":"Kawashima, H. et al. Comparative assessment of predictive performance of PRECISE-DAPT, CRUSADE, and ACUITY scores in risk stratifying 30-day bleeding events. Thromb. Haemost. 120, 1087\u20131095 (2020).","journal-title":"Thromb. Haemost."},{"key":"901_CR54","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/ccd.29352","volume":"97","author":"N Mihatov","year":"2021","unstructured":"Mihatov, N. et al. Utility of the dual antiplatelet therapy score to guide antiplatelet therapy: a systematic review and meta-analysis. Catheter. Cardiovasc. Interv. 97, 569\u2013578 (2021).","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"901_CR55","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1093\/eurheartj\/ehac402","volume":"43","author":"MP Bonaca","year":"2022","unstructured":"Bonaca, M. P. et al. Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54. Eur. Heart J. 43, 5037\u20135044 (2022).","journal-title":"Eur. Heart J."},{"key":"901_CR56","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jacc.2018.11.048","volume":"73","author":"F Costa","year":"2019","unstructured":"Costa, F. et al. Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting. J. Am. Coll. Cardiol. 73, 741\u2013754 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"901_CR57","doi-asserted-by":"crossref","first-page":"e1371","DOI":"10.4244\/EIJ-D-21-00904","volume":"17","author":"DJ Angiolillo","year":"2022","unstructured":"Angiolillo, D. J., Galli, M., Collet, J. P., Kastrati, A. & O\u2019Donoghue, M. L. Antiplatelet therapy after percutaneous coronary intervention. EuroIntervention 17, e1371\u2013e1396 (2022).","journal-title":"EuroIntervention"},{"key":"901_CR58","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ahj.2019.10.001","volume":"220","author":"F D\u2019Ascenzo","year":"2020","unstructured":"D\u2019Ascenzo, F. et al. Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: insights from the BleeMACS and RENAMI registries. Am. Heart J. 220, 108\u2013115 (2020).","journal-title":"Am. Heart J."},{"key":"901_CR59","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jcin.2020.12.005","volume":"14","author":"KH Chau","year":"2021","unstructured":"Chau, K. H. et al. Stent thrombosis risk over time on the basis of clinical presentation and platelet reactivity: analysis from ADAPT-DES. JACC Cardiovasc. Interv. 14, 417\u2013427 (2021).","journal-title":"JACC Cardiovasc. Interv."},{"key":"901_CR60","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ahj.2020.01.014","volume":"223","author":"F Costa","year":"2020","unstructured":"Costa, F. et al. A 4-item PRECISE-DAPT score for dual antiplatelet therapy duration decision-making. Am. Heart J. 223, 44\u201347 (2020).","journal-title":"Am. Heart J."},{"key":"901_CR61","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/ehjcvp\/pvab068","volume":"8","author":"AH Tavenier","year":"2022","unstructured":"Tavenier, A. H. et al. Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis. Eur. Heart J. Cardiovasc. Pharmacother. 8, 492\u2013502 (2022).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"901_CR62","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/eurheartj\/ehac829","volume":"44","author":"J Kang","year":"2023","unstructured":"Kang, J. et al. Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis. Eur. Heart J.\u00a044, 1360\u20131370\u00a0(2023).","journal-title":"Eur. Heart J."},{"key":"901_CR63","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","volume":"125","author":"HC Gwon","year":"2012","unstructured":"Gwon, H. C. et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 125, 505\u2013513 (2012).","journal-title":"Circulation"},{"key":"901_CR64","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","volume":"60","author":"BK Kim","year":"2012","unstructured":"Kim, B. K. et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following endeavor zotarolimus-eluting stent implantation). J. Am. Coll. Cardiol. 60, 1340\u20131348 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"key":"901_CR65","volume":"9","author":"Y Han","year":"2016","unstructured":"Han, Y. et al. Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial. Circ. Cardiovasc. Interv. 9, e003145 (2016).","journal-title":"Circ. Cardiovasc. Interv."},{"key":"901_CR66","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","volume":"391","author":"JY Hahn","year":"2018","unstructured":"Hahn, J. Y. et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet 391, 1274\u20131284 (2018).","journal-title":"Lancet"},{"key":"901_CR67","doi-asserted-by":"crossref","first-page":"k3793","DOI":"10.1136\/bmj.k3793","volume":"363","author":"E Kedhi","year":"2018","unstructured":"Kedhi, E. et al. Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ 363, k3793 (2018).","journal-title":"BMJ"},{"key":"901_CR68","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.4244\/EIJ-D-17-00792","volume":"13","author":"BK Lee","year":"2018","unstructured":"Lee, B. K. et al. Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C randomised clinical trial and OCT substudy. EuroIntervention 13, 1923\u20131930 (2018).","journal-title":"EuroIntervention"},{"key":"901_CR69","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.4244\/EIJ-D-19-00539","volume":"15","author":"G De Luca","year":"2019","unstructured":"De Luca, G. et al. Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial). EuroIntervention 15, e990\u2013e998 (2019).","journal-title":"EuroIntervention"},{"key":"901_CR70","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"P Vranckx","year":"2018","unstructured":"Vranckx, P. et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet 392, 940\u2013949 (2018).","journal-title":"Lancet"},{"key":"901_CR71","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","volume":"321","author":"JY Hahn","year":"2019","unstructured":"Hahn, J. Y. et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA 321, 2428\u20132437 (2019).","journal-title":"JAMA"},{"key":"901_CR72","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1093\/eurheartj\/ehaa670","volume":"41","author":"U Baber","year":"2020","unstructured":"Baber, U. et al. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. Eur. Heart J. 41, 3533\u20133545 (2020).","journal-title":"Eur. Heart J."},{"key":"901_CR73","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","volume":"323","author":"BK Kim","year":"2020","unstructured":"Kim, B. K. et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA 323, 2407\u20132416 (2020).","journal-title":"JAMA"},{"key":"901_CR74","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","volume":"7","author":"H Watanabe","year":"2022","unstructured":"Watanabe, H. et al. Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial. JAMA Cardiol. 7, 407\u2013417 (2022).","journal-title":"JAMA Cardiol."},{"key":"901_CR75","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jcin.2020.11.046","volume":"14","author":"M Valgimigli","year":"2021","unstructured":"Valgimigli, M. et al. Ticagrelor monotherapy versus dual-antiplatelet therapy after PCI: an individual patient-level meta-analysis. JACC Cardiovasc. Interv. 14, 444\u2013456 (2021).","journal-title":"JACC Cardiovasc. Interv."},{"key":"901_CR76","doi-asserted-by":"crossref","first-page":"n1332","DOI":"10.1136\/bmj.n1332","volume":"373","author":"M Valgimigli","year":"2021","unstructured":"Valgimigli, M. et al. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ 373, n1332 (2021).","journal-title":"BMJ"},{"key":"901_CR77","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","volume":"321","author":"H Watanabe","year":"2019","unstructured":"Watanabe, H. et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA 321, 2414\u20132427 (2019).","journal-title":"JAMA"},{"key":"901_CR78","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jacc.2022.07.016","volume":"80","author":"PC Smits","year":"2022","unstructured":"Smits, P. C. et al. Abbreviated antiplatelet therapy after coronary stenting in patients with myocardial infarction at high bleeding risk. J. Am. Coll. Cardiol. 80, 1220\u20131237 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"901_CR79","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1093\/eurheartj\/ehac284","volume":"43","author":"M Valgimigli","year":"2022","unstructured":"Valgimigli, M. et al. Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis. Eur. Heart J. 43, 3100\u20133114 (2022).","journal-title":"Eur. Heart J."},{"key":"901_CR80","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","volume":"38","author":"T Cuisset","year":"2017","unstructured":"Cuisset, T. et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur. Heart J. 38, 3070\u20133078 (2017).","journal-title":"Eur. Heart J."},{"key":"901_CR81","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(20)31791-8","volume":"396","author":"HS Kim","year":"2020","unstructured":"Kim, H. S. et al. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet 396, 1079\u20131089 (2020).","journal-title":"Lancet"},{"key":"901_CR82","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(21)01445-8","volume":"398","author":"CJ Kim","year":"2021","unstructured":"Kim, C. J. et al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet 398, 1305\u20131316 (2021).","journal-title":"Lancet"},{"key":"901_CR83","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(16)31323-X","volume":"388","author":"G Cayla","year":"2016","unstructured":"Cayla, G. et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet 388, 2015\u20132022 (2016).","journal-title":"Lancet"},{"key":"901_CR84","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","volume":"390","author":"D Sibbing","year":"2017","unstructured":"Sibbing, D. et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet 390, 1747\u20131757 (2017).","journal-title":"Lancet"},{"key":"901_CR85","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","volume":"381","author":"DMF Claassens","year":"2019","unstructured":"Claassens, D. M. F. et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N. Engl. J. Med. 381, 1621\u20131631 (2019).","journal-title":"N. Engl. J. Med."},{"key":"901_CR86","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1001\/jamacardio.2022.0052","volume":"7","author":"D Hwang","year":"2022","unstructured":"Hwang, D. et al. Prasugrel dose de-escalation therapy after complex percutaneous coronary intervention in patients with acute coronary syndrome: a post hoc analysis from the HOST-REDUCE-POLYTECH-ACS trial. JAMA Cardiol. 7, 418\u2013426 (2022).","journal-title":"JAMA Cardiol."},{"key":"901_CR87","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcin.2020.01.226","volume":"13","author":"DJ Angiolillo","year":"2020","unstructured":"Angiolillo, D. J. et al. Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score. JACC Cardiovasc. Interv. 13, 606\u2013617 (2020).","journal-title":"JACC Cardiovasc. Interv."},{"key":"901_CR88","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(12)60161-5","volume":"379","author":"JD Roberts","year":"2012","unstructured":"Roberts, J. D. et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 379, 1705\u20131711 (2012).","journal-title":"Lancet"},{"key":"901_CR89","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","volume":"12","author":"D Sibbing","year":"2019","unstructured":"Sibbing, D. et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y(12) receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc. Interv. 12, 1521\u20131537 (2019).","journal-title":"JACC Cardiovasc. Interv."},{"key":"901_CR90","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1093\/eurheartj\/ehy332","volume":"39","author":"D Sibbing","year":"2018","unstructured":"Sibbing, D. et al. Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial. Eur. Heart J. 39, 2749\u20132758 (2018).","journal-title":"Eur. Heart J."},{"key":"901_CR91","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/S0140-6736(21)00533-X","volume":"397","author":"M Galli","year":"2021","unstructured":"Galli, M. et al. Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Lancet 397, 1470\u20131483 (2021).","journal-title":"Lancet"},{"key":"901_CR92","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jcin.2021.11.028","volume":"15","author":"C Laudani","year":"2022","unstructured":"Laudani, C. et al. Short duration of DAPT versus de-escalation after percutaneous coronary intervention for acute coronary syndromes. JACC Cardiovasc. Interv. 15, 268\u2013277 (2022).","journal-title":"JACC Cardiovasc. Interv."},{"key":"901_CR93","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","volume":"372","author":"MP Bonaca","year":"2015","unstructured":"Bonaca, M. P. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N. Engl. J. Med. 372, 1791\u20131800 (2015).","journal-title":"N. Engl. J. Med."},{"key":"901_CR94","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.3390\/jcm10184132","volume":"10","author":"S Garcia-Blas","year":"2021","unstructured":"Garcia-Blas, S. et al. Acute coronary syndrome in the older patient.\u00a0J. Clin. Med. 10, 4132 (2021).","journal-title":"J. Clin. Med."},{"key":"901_CR95","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11886-020-01298-x","volume":"22","author":"WT Kayani","year":"2020","unstructured":"Kayani, W. T., Khan, M. R., Deshotels, M. R. & Jneid, H. Challenges and controversies in the management of ACS in elderly patients. Curr. Cardiol. Rep. 22, 51 (2020).","journal-title":"Curr. Cardiol. Rep."},{"key":"901_CR96","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/eurheartj\/ehac515","volume":"44","author":"F Andreotti","year":"2023","unstructured":"Andreotti, F. et al. Acute, periprocedural and longterm antithrombotic therapy in older adults. Eur. Heart J. 44, 262\u2013279 (2023).","journal-title":"Eur. Heart J."},{"key":"901_CR97","doi-asserted-by":"crossref","first-page":"e1605","DOI":"10.4244\/EIJ-D-19-00699","volume":"15","author":"M Tomaniak","year":"2020","unstructured":"Tomaniak, M. et al. Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial. EuroIntervention 15, e1605\u2013e1614 (2020).","journal-title":"EuroIntervention"},{"key":"901_CR98","first-page":"400","volume":"30","author":"B Patel","year":"2017","unstructured":"Patel, B., Shah, M., Dusaj, R., Maynard, S. & Patel, N. Percutaneous coronary intervention and inpatient mortality in patients with advanced chronic kidney disease presenting with acute coronary syndrome. Proc. (Bayl. Univ. Med. Cent.) 30, 400\u2013403 (2017).","journal-title":"Proc. (Bayl. Univ. Med. Cent.)"},{"key":"901_CR99","volume":"4","author":"T Gupta","year":"2015","unstructured":"Gupta, T. et al. Association of chronic renal insufficiency with in-hospital outcomes after percutaneous coronary intervention. J. Am. Heart Assoc. 4, e002069 (2015).","journal-title":"J. Am. Heart Assoc."},{"key":"901_CR100","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.amjcard.2021.07.018","volume":"157","author":"A Latif","year":"2021","unstructured":"Latif, A. et al. Meta-analysis of transradial versus transfemoral access for percutaneous coronary intervention in patients with chronic kidney disease. Am. J. Cardiol. 157, 8\u201314 (2021).","journal-title":"Am. J. Cardiol."},{"key":"901_CR101","doi-asserted-by":"crossref","first-page":"106858","DOI":"10.1016\/j.vph.2021.106858","volume":"138","author":"G Gelbenegger","year":"2021","unstructured":"Gelbenegger, G. et al. Optimal duration and combination of antiplatelet therapies following percutaneous coronary intervention: a meta-analysis. Vasc. Pharmacol. 138, 106858 (2021).","journal-title":"Vasc. Pharmacol."},{"key":"901_CR102","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.jacc.2020.03.011","volume":"75","author":"G Dangas","year":"2020","unstructured":"Dangas, G. et al. Ticagrelor with or without aspirin after complex PCI. J. Am. Coll. Cardiol. 75, 2414\u20132424 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"901_CR103","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-57030","author":"DA Gorog","year":"2023","unstructured":"Gorog, D. A. et al. Comparison of de-escalation of DAPT intensity or duration in East Asian and Western patients with ACS undergoing PCI: a systematic review and meta-analysis. Thromb. Haemost. https:\/\/doi.org\/10.1055\/s-0043-57030 (2023).","journal-title":"Thromb. Haemost."},{"key":"901_CR104","volume":"16","author":"JW Tan","year":"2021","unstructured":"Tan, J. W. et al. 2020 Asian Pacific Society of Cardiology consensus recommendations on the use of P2Y12 receptor antagonists in the Asia-Pacific region. Eur. Cardiol. 16, e02 (2021).","journal-title":"Eur. Cardiol."},{"key":"901_CR105","volume":"16","author":"JWC Tan","year":"2021","unstructured":"Tan, J. W. C. et al. 2021 Asian Pacific Society of Cardiology consensus recommendations on the use of P2Y12 receptor antagonists in the Asia-Pacific region: special populations. Eur. Cardiol. 16, e43 (2021).","journal-title":"Eur. Cardiol."},{"key":"901_CR106","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/ehjcvp\/pvaa005","volume":"7","author":"SH Lee","year":"2021","unstructured":"Lee, S. H. et al. Practical guidance for P2Y12 inhibitors in acute myocardial infarction undergoing percutaneous coronary intervention. Eur. Heart J. Cardiovasc. Pharmacother. 7, 112\u2013124 (2021).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"901_CR107","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4244\/EIJ-D-22-00886","volume":"19","author":"NMR van der Sangen","year":"2023","unstructured":"van der Sangen, N. M. R. et al. Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study. EuroIntervention\u00a019, 63\u201372\u00a0(2023).","journal-title":"EuroIntervention"}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41569-023-00901-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-023-00901-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-023-00901-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T14:14:23Z","timestamp":1699884863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41569-023-00901-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":107,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["901"],"URL":"https:\/\/doi.org\/10.1038\/s41569-023-00901-2","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,20]]},"assertion":[{"value":"7 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.A.G. reports institutional research grants from Alpha MD,\u00a0AstraZeneca, Bayer, Medtronic and Werfen, and speaker fees from AstraZeneca. J.L.F. reports speaker fees from Abbott, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Ferrer, Pfizer, Roche Diagnostics, Rovi and Terumo; consulting fees from AstraZeneca, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Ferrer and Pfizer; and a research grant from AstraZeneca. J.A. reports speaking honoraria from AstraZeneca, Bayer and Daiichi Sankyo. T.G. reports speaker and consultant fees or research grants from AstraZeneca, Bayer, BMS\/Pfizer, Boehringer Ingelheim, Daiichi Sankyo, Edwards Lifescience, Ferrer\/Chiesi and Medtronic. S.H. reports speaker fees from AstraZeneca, BMS\/Pfizer, Novartis and Sanofi. No fees were received personally. Y.H.J. reports speaker fees from Daiichi Sankyo, Han-mi Pharmaceutical, JW Pharmaceutical, and Sanofi Aventis and research grants from Biotronik, Han-mi Pharmaceuticals, Sam-jin Pharmaceuticals, U&I Corporation and Yuhan Pharmaceuticals. E.P.N. reports research grants from Abbott and Amgen and lecture fees\/honoraria from Amgen, AstraZeneca, Bayer, Pfizer and Sanofi-Regeneron. D.S. reports speaker fees and fees for advisory board activities from Bayer and Sanofi Aventis. J.M.S.-M. reports speaker or consultant fees from Biosensors, Boehringer Ingelheim, Boston Scientific, Chiesi, Daiichi Sankyo and P&F. R.F.S. reports institutional research grants\/support from AstraZeneca, Cytosorbents, GlyCardial Diagnostics and Thromboserin, and personal fees from Alnylam, AstraZeneca, Bayer, Bristol Myers Squibb\/Pfizer, Chiesi, CSL Behring, Cytosorbents, Daiichi Sankyo, GlyCardial Diagnostics, Hengrui, Idorsia, Intas Pharmaceuticals, Medscape, Novartis, PhaseBio, Sanofi Aventis and Thromboserin. J.W.C.T. reports honoraria from Abbott Vascular, Alvimedica, Amgen, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Medtronic and Pfizer; research and educational grants from Abbott Vascular, Amgen, AstraZeneca, Biosensors, Biotronik, Medtronic, Otsuka, Philips, Roche and Terumo; and consulting fees from CSL Behring and Elixir. J.M.t.B. reports advisory\/consulting\/speakers fees from AstraZeneca, Bayer, BMS, Boehringer Ingelheim, CeleCOR Daiichi Sankyo, Eli Lilly, Ferrer, and Pfizer and institutional research grants from AstraZeneca, Daiichi Sankyo and ZonMw (Dutch Government). M.V. reports grants from Terumo and personal fees from Abbott Vascular, Alvimedica\/CID, AstraZeneca, Bayer, Biotronik, Boston Scientific, Bristol Myers Squibb SA, Chiesi, CoreFLOW, Daiichi Sankyo, ECRI, IDORSIA Pharmaceuticals, Medscape, Medtronic, Novartis, PhaseBio, Terumo, Universit\u00e4t Basel, Dept. Klinische Forschung, Vesalio and Vifor. C.V. reports speaker fees from Bayer, Boehringer Ingelheim and Daiichi Sankyo. G.Y.H.L. reports consultant and speaker activities for Anthos, BMS\/Pfizer, Boehringer Ingelheim and Daiichi Sankyo. No fees were received personally. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}